Browse the evidence

During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.

If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.

Combination therapy using atomoxetine and oxybutynin reduces OSA severity by approximately 60% by activating pharyngeal dilator muscles.

This combination drug is currently in clinical trials (Phase III) and not yet widely available. It targets the muscle function aspect of sleep apnea. If you are not a candidate for CPAP or weight loss drugs, you may want to ask your doctor about upcoming clinical trials for this specific combination.

Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.

If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.

Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.

Focus on strategies that may support metabolic health and energy expenditure, such as exposure to cold or specific dietary patterns, as these may influence brown fat activity. However, consult a healthcare provider for personalized advice, as this is a complex physiological area.

Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.

Understanding leptin resistance highlights why simple calorie counting might fail. It suggests that metabolic health, including blood-brain barrier integrity and receptor sensitivity, is crucial. Work with a healthcare provider to address underlying metabolic health.

GLP-1 receptor agonists (semaglutide and liraglutide) are primarily requested by the public for off-label cosmetic weight loss, often without prescriptions or medical advice, creating a high risk of misuse and safety concerns.

GLP-1 medications like semaglutide and liraglutide are powerful tools for weight management and diabetes, but they are not cosmetic shortcuts. Most requests for these drugs are for weight loss without a prescription, which poses safety risks. If you are considering these medications, consult a healthcare provider to ensure they are appropriate for your health needs and to receive proper guidance on usage and side effects.

GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.

Current pharmacovigilance data does not support a causal link between GLP-1 or dual incretin weight-loss drugs and suicidal ideation or attempts. While patients should be monitored as standard practice, the absolute risk appears neutral compared to other anti-obesity medications.

Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.

Naltrexone/bupropion shows a higher reporting signal for suicidality compared to GLP-1 drugs, which is consistent with its known pharmacology. Patients using this medication should be monitored for mood changes.

Semaglutide and liraglutide have similar anti-hyperglycemic efficacy, with no consistent significant difference in HbA1c reduction between the two drugs.

For patients with type 2 diabetes, choosing between semaglutide and liraglutide should likely be based on weight loss goals and injection frequency preference, as both drugs lower blood sugar similarly.

Duodenal Mucosal Resurfacing (DMR) significantly improves glycaemic control in Type 2 Diabetes patients by enhancing insulin sensitivity.

Duodenal Mucosal Resurfacing (DMR) is a new, minimally invasive procedure that can help lower blood sugar in Type 2 Diabetes. It works by treating the duodenum to improve insulin sensitivity. Clinical trials show it reduces HbA1c levels, and the more duodenum treated, the better the result. It is a safe option for those who may not respond well to standard treatments.

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.

Off-label use of GLP-1 receptor agonists (specifically semaglutide) for weight loss can precipitate euglycemic starvation ketoacidosis in non-diabetic individuals, primarily through gastrointestinal side effects causing reduced oral intake and starvation.

If you are using GLP-1 medications like semaglutide for weight loss, do not source them from unregulated online pharmacies. The risk of receiving counterfeit or improperly dosed products is real and can lead to severe metabolic issues. If you experience persistent nausea, vomiting, or inability to eat, seek medical attention immediately, as this can lead to euglycemic ketoacidosis—a dangerous condition where your blood becomes acidic despite normal blood sugar levels. Never ignore severe gastrointestinal side effects.

Post-market surveillance is investigating potential links between GLP-1 receptor agonists and suicidal ideation, as well as an increased risk of thyroid cancer of all histologic subtypes.

Stay informed about post-market surveillance findings. The FDA has issued warnings regarding suicidal behavior, and studies suggest a higher risk of thyroid cancer. Discuss these risks with your healthcare provider and follow current evidence-based counseling.

Dietary supplementation with Docosahexaenoic acid (DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing Betacellulin (BTC) expression, thereby inhibiting the BTC-EGFR-ERBB pathway, reducing hepatic stellate cell proliferation, and lowering TGFβ-2-mediated collagen production.

If you are managing NASH or liver health, the specific type of Omega-3 matters. Research indicates DHA is more effective than EPA at suppressing key liver damage pathways (like Betacellulin and TGFβ-2). While this study is in mice, it suggests prioritizing DHA-rich sources or supplements over generic Omega-3 blends for liver-specific benefits.

GLP-1 receptor agonists (GLP1RAs) do not increase the risk of adverse events compared to other anti-obesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight regain, current data indicates they are not more dangerous than other standard weight loss drugs. The risk of serious complications is low and similar to other options. However, starting these medications more than 12 months after surgery appears to have a lower risk of adverse events than starting them earlier.

Systemic administration of the GIP receptor agonist DA-GIP suppresses inflammation-induced conditioned taste avoidance (CTA) and reduces parabrachial CGRP neuron activation, acting via distinct neural circuits than its anorectic effects.

For individuals experiencing severe nausea or food aversion due to inflammation (e.g., chronic autoimmune conditions or post-infection), standard anti-nausea medications (like ondansetron) or anti-inflammatories (NSAIDs) may not fully resolve the aversion. Emerging GIP-based therapies show promise in specifically targeting the neural circuits responsible for this aversion without necessarily worsening appetite suppression, potentially improving quality of life during inflammatory episodes.

GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.

Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.

Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.

This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.

Tirzepatide demonstrates greater clinical potency than semaglutide, potentially due to glucose-dependent insulinotropic polypeptide (GIP) receptor activation increasing energy expenditure.

If you are struggling with weight loss on a GLP-1 drug like semaglutide, ask your doctor about tirzepatide. It targets two hormones (GIP and GLP-1) instead of just one, which may lead to greater weight loss for some people by increasing how much energy you burn.

In patients with Type 2 Diabetes and Heart Failure with reduced ejection fraction (HFrEF), treatment with GLP-1 receptor agonists significantly reduces all-cause mortality and major cardiovascular events compared to DPP-4 inhibitors.

If you have Type 2 Diabetes and reduced heart function (HFrEF), GLP-1 medications (like semaglutide or dulaglutide) are associated with a significantly lower risk of death and heart-related hospitalizations compared to DPP-4 inhibitors. This benefit appears early and persists over 5 years, regardless of age or sex. Discuss these options with your cardiologist, as they may offer cardiovascular protection beyond blood sugar control.

A single meal containing 72g of digestible carbohydrates inhibits ketosis (lipolysis) for several days, with recovery time dependent on baseline fasting insulin levels.

If you are relying on ketosis for fat loss, avoid high-carb meals entirely. A single meal with ~72g of carbs (e.g., bread and jam) can stop fat burning for 2 to 5 days, or indefinitely if your fasting insulin is high. Recovery time depends on your metabolic health; those with higher insulin levels may never recover ketosis within a standard 2-week window.